Example SOP for Power Failure in a Pharma Plant

In short: This illustrative SOP template helps pharmaceutical teams respond to an electrical power interruption. Secure people, materials, records and equipment, document what happened, and assess the impact before resuming work. Site Quality, Engineering and process owners must adapt and approve the procedure for their own systems.

1. Purpose

To describe a site-adaptable response to a power interruption affecting production, laboratories, utilities, storage or supporting systems. This is an example SOP, not a substitute for an approved site procedure, equipment instructions, product-specific requirements or emergency plans.

2. Scope

This template may be adapted for manufacturing, packaging, sampling, dispensing, QC and microbiology laboratories, pharmaceutical water systems, stability chambers and controlled environments. Define which areas, critical systems and backup supplies are covered at the site.

3. Responsibilities

• All personnel: protect people first, stop work safely when needed, secure exposed materials where safe, and promptly report the interruption.
• Production, QC, Microbiology, Stores and Utilities: document the interruption and affected operations; preserve relevant batch, equipment, environmental and utility records.
• Engineering/Utilities: assess the electrical supply and affected equipment or utility systems, and document their readiness for use.
• Quality Assurance (QA): coordinate or review the impact assessment, deviation and disposition decisions under the site’s approved quality system.
• Area and process owners: define product- and equipment-specific safe states, recovery checks and restart criteria in approved procedures.

4. Procedure

4.1 Immediate response

1. Protect personnel. Follow the site’s emergency response instructions if the interruption creates a safety hazard. Do not operate or reset equipment if its condition is uncertain or doing so could create a hazard.
2. Stop or place affected operations in a safe state using approved equipment instructions. Do not bypass interlocks or defeat alarms.
3. Close or otherwise protect exposed materials and products using approved handling practices. Identify and segregate affected items when their status is uncertain; maintain traceability and required storage conditions.
4. Notify the area supervisor and Engineering/Utilities. Notify QA according to the site’s escalation procedure.
5. Record the date and time of loss and restoration of power, affected locations and equipment, active process step, material or batch identifiers, alarms, backup-power response, and any environmental or utility interruption. Preserve available electronic records and alarm/event logs.

4.2 Impact assessment and disposition

1. Open a deviation or incident record in accordance with the site’s quality system. See SOP on handling incidents and deviations.
2. With Engineering/Utilities and the process owner, assess the duration and extent of interruption; equipment state and alarms; process parameters and elapsed times; environmental conditions; critical utilities; backup-power performance; and any loss or interruption of monitoring, control or electronic data.
3. Identify all potentially affected materials, in-process product, finished product, samples, records and equipment. Maintain segregation and appropriate storage until disposition is documented.
4. QA and the responsible process owner should document the scientific rationale, any required investigation, testing or reprocessing assessment, and the disposition decision. Do not resume or release affected work solely because electrical power has returned.
5. Document corrective and preventive actions where warranted. For batch disposition context, see SOP for batch release of finished product.

4.3 System-specific recovery

Use approved, system-specific recovery instructions. The following are assessment prompts; they do not establish universal acceptance criteria.

• Production and packaging equipment: verify equipment condition, settings, guards, alarms and process records; reconcile material remaining in hoppers, feed paths, pans or packaging equipment; assess whether in-process material can continue under the approved batch record. Document any rejected or sampled units and the rationale.
• Controlled rooms and local air-protection equipment: assess the status of HVAC, pressure relationships, temperature, humidity and any local protection or monitoring that may have been affected. Restart only after the approved area-specific recovery criteria are met and documented.
• Sampling and dispensing: protect open containers and samples, record exposure and identify the status of materials. Confirm the relevant environmental controls and local protection are operating as required by the approved procedure before resuming.
• Pharmaceutical water systems: follow the qualified system’s approved response and recovery procedure. Assess system alarms, operation, monitoring data and water quality against the applicable approved specification and sampling plan. Do not release water for use based only on pH or conductivity. WHO recommends control of water quality throughout production, storage and distribution, with written-procedure-based monitoring (WHO TRS 1033, Annex 3, 2021). See Guide to inspections of high-purity water systems.
• Stability chambers and other controlled storage: document chamber conditions and the time and extent of any excursion; identify affected studies or materials and assess impact under the applicable protocol. ICH Q1A(R2) says excursions due to equipment failure should be addressed and reported if judged to affect stability results; excursions beyond defined storage-condition tolerances for more than 24 hours should be described in the study report and their effect assessed. This is not a universal outage trigger. See SOP for recording temperature and humidity of stability chambers.
• Sterile operations and microbiology areas: follow the approved contamination-control strategy and site-specific recovery procedure. Assess the power and monitoring status of critical systems and the process stage; determine any required environmental or personnel monitoring and investigation with QA. Do not use historical room classifications or generic counts as restart limits.
• Instruments and electronic systems: assess whether power interruption could affect calibration status, configuration, data integrity or ongoing measurements. Perform checks, recovery or calibration only where justified by the instrument procedure and documented assessment; do not automatically recalibrate every instrument.

4.4 Restart and closure

1. Engineering/Utilities documents that the relevant supply, equipment and utilities are restored and safe. The process owner confirms applicable process and environmental requirements using current approved records and procedures.
2. QA and the responsible area owner document authorization to resume, any additional controls, and the disposition of affected material. Restart decisions and criteria are site-specific and must be approved before use of this template.
3. Record restart time, checks performed, results, personnel, deviations and follow-up actions in the relevant batch record, equipment log, utility log or incident record.
4. Close the incident after required investigations, impact assessments, disposition and actions are complete. Retain records under the site’s document-retention procedure.

5. Source-template values (example in-house criteria)

The imported source included the following example in-house criteria. They are preserved here for Admin review only; they are not established by the sources cited in this article and must not be used as operational instructions without site-specific verification and approval.

• Example in-house criterion (not a regulatory requirement): the imported source used outage triggers of more than 10 minutes for several manufacturing and laboratory areas, more than 5 minutes for a dry-powder injectable area, and more than 24 hours for stability chambers. No official source cited here sets these durations. Each site must justify any trigger scientifically per area/system, approve it in the SOP, and define the response (documented assessment by Production, Engineering and QA) for interruptions shorter than the trigger. For stability chambers, the ICH Q1A(R2) 24-hour reference applies to excursions beyond storage-condition tolerances, not to power outages generally.
• Example in-house criterion (not a regulatory requirement): the imported source specified waiting periods of 20 minutes for many areas and 10 minutes for RLAF/MLT recovery, and said to discard the first two compression-machine rotation tablets. Recovery periods and discard instructions must be taken from validated equipment and process procedures and approved batch records, and set by qualification or recovery studies; do not adopt these figures without that justification.
• For a dry-powder injectable area, the source gave “Class 100/1000/10000” non-viable particle limits of 3,520/35,200/352,000 particles/m³ at a garbled particle size “³5 m,” and 29/293/2,930 particles/m³ at the garbled size “³0 m”; it also gave viable results of less than 1, not more than 3, and not more than 5 cfu/plate, respectively.
• The source said to sanitize and sample every water user point after an outage, then permit use based on pH and conductivity alone.
• The source directed environmental monitoring after interruptions in sterile/MLT rooms and local disinfection after recovery.
• The source directed recalibration of every instrument after a power failure.

6. Abbreviations

• BMR: batch manufacturing record
• CAPA: corrective and preventive action
• CFU: colony-forming units
• HVAC: heating, ventilation and air conditioning
• MLT: microbiological limit test
• QA: Quality Assurance
• QC: Quality Control
• RLAF: reverse laminar airflow

References

• International Council for Harmonisation (ICH), Stability Testing of New Drug Substances and Products, Q1A(R2), Step 4, 2003. Official guideline
• World Health Organization (WHO), Good manufacturing practices: water for pharmaceutical use, WHO Technical Report Series No. 1033, Annex 3, 2021. Official guideline